Blog Archives
Largest CRISPR/Cas9-mediated deletion relevant to 60% of DMD mutations
Mutations in DMD disrupt the reading frame, prevent dystrophin translation, and cause Duchenne muscular dystrophy (DMD). Here the authors describe a CRISPR/Cas9 platform applicable to 60% of DMD patient mutations. They applied the platform to DMD-derived hiPSCs where successful deletion and non-homologous end joining of up to 725 kb reframed the DMD gene. This is … [Read more]
NMR and functional assessments of upper limbs in DMD
This study aimed to explore the value of nuclear magnetic resonance (NMR) and functional assessments for follow-up of ambulatory and nonambulatory patients with Duchenne muscular dystrophy (DMD). Twenty-five 53-skippable patients with DMD were included in this study; 15 were nonambulatory at baseline. All patients underwent clinical and functional assessments every 6 months using the … [Read more]
Clinical trials of dichlorphenamide in periodic paralysis
Two multicenter randomised, double-blind, placebo-controlled trials were carried out to determine the short-term and long-term effects of dichlorphenamide (DCP) on attack frequency and quality of life in hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis. The trials, which included 44 HOP and 21 HYP participants, lasted 9 weeks and were followed by a 1-year extension phase … [Read more]
Positive results with nusinersen in children with SMA
Nusinersen (previously ISIS-SMNRx) is an antisense oligonucleotide designed to bind to the SMN2 pre-mRNA and promote inclusion of exon 7. This first-in-human, open-label, single- ascending dose study was designed to examine safety, tolerability, pharmacokinetics, and preliminary clinical effects of intrathecal nusinersen in medically stable patients (aged 2-14 years) with type 2 and type 3 spinal … [Read more]
Biomarkers for SMA progression identified
In this study, the authors aimed to determine the feasibility and reliability of testing specific putative physiological and molecular spinal muscular atrophy (SMA) biomarkers in infants with SMA (n=26) and in age‐matched healthy control infants (n=27). Recruitment occurred at 14 centers within the NINDS National Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Network. Infant … [Read more]
Role of activating signal cointegrator 1 complex in the development of the peripheral nervous system
Transcriptional signal cointegrators associate with transcription factors or nuclear receptors and coregulate tissue-specific gene transcription. This study reports on recessive loss-of-function mutations in two genes (TRIP4 and ASCC1) that encode subunits of the nuclear activating signal cointegrator 1 (ASC-1) complex. Autozygosity mapping and whole-exome sequencing were used to search for pathogenic mutations in four families. … [Read more]
An outstanding result for Telethon 2015: 93,850,778 €!
The final amount of money collected during Telethon 2015 has just come up: 93,850,778€ were collected thanks to the national rallying from all participants. Thanks to this amount, researchers and families of patients will be able to carry on with their fight against rare diseases. This result is even more outstanding that this 29th edition … [Read more]
Myology 2016 – Review
Myology 2016 : the beginning of the therapeutic era for neuromuscular diseases Myology 2016, the international congress of myology organized by AFM-Téléthon has ended last week. It gathered 982 international experts in the field (researchers, clinicians, doctors…) have compared their latest work for 5 days. This edition was undoubtedly marked by the beginning of the therapeutic … [Read more]
Myology 2016 – March 18th
The congress Myology 2016, organised by AFM-Téléthon, is now coming to an end with a focus on the heart and advanced therapies. Plenary session « Heart » Now again, we’ve witnessed presentations on the advances and the projects of gene and cell therapies for the heart, whether for cardiomyopathies or post-infarction heart failure. Therefore, Philippe Menasché (HEGP, … [Read more]
Myology 2016 – March 17th
Plenary session « Advances in Myology » The fourth day of Myology 2016 opened on a plenary session dedicated to the different myology-related advances. H. Lee Sweeney from the University of Florida (USA), co-chairman of the congress, overviewed the trials using oligonucleotides in Duchenne muscular dystrophy. He underlined the need, for demonstrating the efficiency of products currently … [Read more]